Business Description
SCYNEXIS is a US-based biotechnology company focused on fighting fungal infections that are hard to treat or resistant to existing medicines. Its main product, BREXAFEMME, is approved to treat and help prevent recurring vaginal yeast infections. The company is also advancing SCY-247, an experimental therapy currently in early-stage clinical trials for serious internal fungal infections. Founded in 1999 and based in Jersey City, New Jersey, SCYNEXIS has built its business around addressing a significant gap in antifungal treatment options.
